New York, Jan 17, 2026, 16:53 EST — Market closed.
Intuitive Surgical (ISRG.O) shares closed Friday down 1.2% at $535, marking a fifth straight session of losses as volume outpaced recent averages. The stock traded in a range from $532.63 to $542.99 during the day, while medtech peers showed mixed results. (MarketWatch)
U.S. stock markets were closed Monday for Martin Luther King Jr. Day, leaving investors to start a shortened week still digesting recent figures from the surgical-robot maker. Trading picks up again Tuesday. (New York Stock Exchange)
The immediate focus is on pace, not only the dollar amounts. Intuitive’s revenue depends heavily on recurring sales linked to “procedures” — the surgeries performed with da Vinci systems — since every case drives demand for instruments, accessories, and service.
Intuitive provided a preliminary look at its fourth-quarter figures, reporting revenue near $2.87 billion—a 19% jump from last year. The company also noted a 17% increase in da Vinci procedures. During the quarter, it placed 532 systems, with 303 being the new da Vinci 5 models. Looking ahead, Intuitive projects global procedure growth between 13% and 15% for 2026. The full fourth-quarter results are set for release on Jan. 22. (Nasdaq)
Executives are driving one key point: da Vinci 5 is seeing higher usage. CEO Dave Rosa told investors that U.S. utilization of da Vinci 5 runs 11% above the older Xi model, calling the rollout “exceeded” expectations. CFO Jamie Samath highlighted strong after-hours cases, especially gallbladder and appendectomy surgeries. Rosa also signaled looming competition, noting Medtronic’s Hugo system recently cleared in the U.S. for urology, while Johnson & Johnson’s Ottava is under FDA review for general surgery. (MedTech Dive)
That combination paves the way for the upcoming session. Traders are watching closely for shifts in the 2026 procedure-growth range, updates on da Vinci 5 placements, and signals about upgrade demand. They’ll also be tracking whether hospitals prefer leasing and usage-based contracts over outright buys.
Margins will be crucial as well. Investors have come to see a robust quarter of system shipments as a double-edged sword: selling more systems supports near-term revenue, yet the product mix and rollout expenses can weigh on profits.
The downside is straightforward. Should procedure growth falter beyond management’s forecasts, or if hospitals cut back on capital expenditures as competitors enter the scene, the recent slide in the stock might extend into a prolonged reset. This risk grows if recurring revenue growth also stalls.
U.S. markets reopen Tuesday, though the spotlight this week falls on Intuitive’s Jan. 22 earnings and conference call. Investors will be eager for sharper insights into demand patterns and the outlook for 2026.
